Quarterly ResultAug 4, 2026, 08:04 AM
Fresenius Medical Care Files Q2 2026 Interim Report; Details Reclassification
AI Summary
Fresenius Medical Care AG filed its interim report for the three and six months ended June 30, 2026 and 2025, including unaudited consolidated financial statements and management's discussion and analysis. The company announced a Pharmaceutical Business Reclassification, moving certain activities from the Care Enablement to the Care Delivery segment. Additionally, the FME25+ Program aims for €1.2 billion in sustainable savings by the end of 2027, with an extra €400 million from operational efficiencies.
Key Highlights
- Filed interim report for three and six months ended June 30, 2026 and 2025.
- Pharmaceutical Business Reclassification moved activities to Care Delivery segment.
- FME25+ Program targets €1.2 BN in sustainable savings by end of 2027.
- Program includes an additional €400 M from operational efficiencies.
- Report contains unaudited consolidated financial statements.
Price Impact
More from FMS